Kevetrin, our lead product candidate, is a small molecule compound proprietary to the company initially being developed to treat head and neck cancers. There is a potential for use of Kevetrin in Multiple tumor types. Kevetrin was discovered by the company’s founder Dr. Krishna Menon. Kevetrin has been studied extensively in vitro and in vivo. Kevetrin’s mechanism of action is through multiple biological pathways as an alkalating agent and an LTB4 inhibitor with anti-angiogenic properties. It has shown to be a potential anti-cancer agent against various cancer cell lines both in vitro and in vivo. Since the compound works through MOA (Multiple Mechanisms of Action) a single compound can attack the progress of cancer through multiple biological pathways, as well as it may have a positive impact on other diseases. These MOAs have a better potential to attack the cancer cells through a variety of pathways that effect the multiplication and formation of the cancer cells along with interruption of the formation of new blood vessels that supply vital nutrients to tumor cells and sustain the tumor growth.
- Small molecule drug that falls under the group of miscellaneous drugs as well as Alkalating agents
- Anti-tumor effect is also achieved by anti-angiogenesis and inhibition of LTB4 pathways
- Multi-targeting mechanism
- Demonstrated success in more than 5,000 small animal tests, achieving tumor shrinkage 60% more effective than radiation alone in head and neck cancers and 40% more effective than Taxol in breast cancer
- In conjunction with radiation, tumor shrinkage is nearly 80%
|
